SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001731122-24-001537
Filing Date
2024-10-03
Accepted
2024-10-03 16:30:53
Documents
14
Period of Report
2024-09-30
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K e6003_8-k.htm   iXBRL 8-K 24301
2 EXHIBIT 10.1 e6003_ex10-1.htm EX-10.1 19886
  Complete submission text file 0001731122-24-001537.txt   225665

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE vrpx-20240930.xsd EX-101.SCH 3027
4 XBRL LABEL FILE vrpx-20240930_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE vrpx-20240930_pre.xml EX-101.PRE 24173
16 EXTRACTED XBRL INSTANCE DOCUMENT e6003_8-k_htm.xml XML 3806
Mailing Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312
Business Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 610-727-4597
Virpax Pharmaceuticals, Inc. (Filer) CIK: 0001708331 (see all company filings)

IRS No.: 821510982 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40064 | Film No.: 241351982
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)